Most recently, in the PARAGON-HF trial, angiotensin receptor–neprilysin inhibitor sacubitril-valsartan was tested in patients with HFpEF, but treatment failed to reduce the combined endpoint of HF hospitalization and death from cardiovascular causes (17). This evidence concerns the gene MME and hydrops fetalis.